BioIntelliSense
Golden
About BioIntelliSense
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM) and Health Screening. BioIntelliSense's medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics, and symptomatic events through an effortless patient experience. The FDA-cleared BioSticke and BioButton devices make remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical-grade care from the hospital to the home, and all points in-between.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $84.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2021)
- Website: biointellisense.com
- Phone: 888-908-8804
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/biointellisense-147621 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.